Jupiter Neurosciences Inc (JUNS) FinancialsJUNSJupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS) generates its revenue primarily from Premium Nutritional Supplements, which accounts for 100.0% of total sales, equivalent to $18.65K. Understanding this concentration is critical for investors evaluating how JUNS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Jupiter Neurosciences Inc maintains a gross margin of 86.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11313.45%, while the net margin is -9380.89%. These profitability ratios, combined with a Return on Equity (ROE) of -1888.70%, provide a clear picture of how effectively JUNS converts its operational activities into shareholder value.

In the context of the broader market, JUNS competes directly with industry leaders such as DRMA and PULM. With a market capitalization of $4.67M, it holds a significant position in the sector. When comparing efficiency, JUNS's gross margin of 86.88% stands against DRMA's N/A and PULM's N/A. Such benchmarking helps identify whether Jupiter Neurosciences Inc is trading at a premium or discount relative to its financial performance.

Jupiter Neurosciences has reported zero revenue for several quarters and significant net losses, including a net loss of $2.27 million in Q2 2026, which is slightly worse than the previous year's loss of $2.25 million. The gross margin has shown some improvement, reaching 86.88% in Q2 2026, but this is overshadowed by the overall financial instability.